Actively Recruiting
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Led by Novartis Pharmaceuticals · Updated on 2025-06-06
200
Participants Needed
7
Research Sites
1043 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This will be a multicenter, national, non-interventional, prospective cohort study
CONDITIONS
Official Title
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who received tisagenlecleucel infusion in the commercial setting or out-of-specification use
- Signed informed consent obtained prior to participation
- For ALL patients aged 0-17 years with relapsed/refractory B-cell ALL who received tisagenlecleucel infusion
- For ALL patients aged 18-25 years with relapsed/refractory B-cell ALL who received tisagenlecleucel infusion
- For DLBCL and FL patients aged 18 years or older with relapsed/refractory disease who received tisagenlecleucel infusion
You will not qualify if you...
- Patients who did not consent to data collection
- Patients who received tisagenlecleucel infusion as part of any interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Novartis Investigative Site
Minas Gerais, Belo Horizonte, Brazil, 34006-059
Actively Recruiting
2
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil, 41253-190
Actively Recruiting
3
Novartis Investigative Site
Curitiba, Paraná, Brazil, 81520-060
Actively Recruiting
4
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 01323-900
Actively Recruiting
5
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 04544-000
Actively Recruiting
6
Novartis Investigative Site
São Paulo, Brazil, 01409-902
Actively Recruiting
7
Novartis Investigative Site
São Paulo, Brazil, 01509-010
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here